SciELO - Scientific Electronic Library Online

 
vol.33 issue5Clinical relevance of oxidative stress and sperm chromatin damage in male infertility: an evidence based analysisPhase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma author indexsubject indexarticles search
Home Pagealphabetic serial listing  

International braz j urol

Print version ISSN 1677-5538

Abstract

PICCOLI, Michelly F. et al. Lack of association between matrix metalloproteinase-1 (MMP-1) promoter polymorphism and risk of renal cell carcinoma. Int. braz j urol. [online]. 2007, vol.33, n.5, pp. 622-629. ISSN 1677-5538.  http://dx.doi.org/10.1590/S1677-55382007000500003.

OBJECTIVE: Investigate the possible association of insertion/deletion (2G/G) polymorphism at nucleotide -1607 of the MMP-1 promoter with the development and progression of renal cancer MATERIALS AND METHODS: In this study, we genotyped 217 individuals, 99 patients with renal cell carcinoma (RCC) and 118 controls without cancer. DNA specimens were extracted from epithelial buccal cells and paraffin-embedded tissue of RCC patients and from epithelial buccal cells and blood cells of healthy controls RESULTS: The difference in frequency of 2G/2G genotype between controls (22.9%) and RCC patients (28.6%) was not statistically significant (p = 0.461). We also did not find correlation between 2G/2G and histological type of RCC. The comparison of genotype distribution and frequency of 2G allele in different populations showed a strong variability of 2G allele frequency among the different ethnic groups. This fact may influence on the collaboration of this 2G allele in RCC or others diseases CONCLUSION: Our data suggest that the matrix metalloproteinase-1 (MMP-1) promoter polymorphism may not play a significant role in renal cell carcinoma patients in Brazil.

Keywords : MMP-1; polymorphism; renal cell carcinoma.

        · text in English     · pdf in English